Dr. Anselmo Bertetti (@anselmobertetti) 's Twitter Profile
Dr. Anselmo Bertetti

@anselmobertetti

Oncología Clínica & Investigación Clínica | 🇦🇷 |
Director Médico del Centro de Radioncología Reconquista
linkedin.com/in/anselmobert…

ID: 1136756245434683392

linkhttps://oncoreconquista.com.ar/ calendar_today06-06-2019 22:06:23

3,3K Tweet

2,2K Takipçi

5,5K Takip Edilen

Dr. Iván R. González (@dr_ivanoncologo) 's Twitter Profile Photo

🚨 Bladder Cancer Breakthrough: Immunotherapy Combo Enables Organ Preservation 🧬 🎯 Objective: Evaluate the efficacy of neoadjuvant sacituzumab govitecan (SG) combined with pembrolizumab (Pembro), followed by response-adapted bladder-sparing strategies and adjuvant Pembro in

🚨 Bladder Cancer Breakthrough: Immunotherapy Combo Enables Organ Preservation 🧬

🎯 Objective: Evaluate the efficacy of neoadjuvant sacituzumab govitecan (SG) combined with pembrolizumab (Pembro), followed by response-adapted bladder-sparing strategies and adjuvant Pembro in
Michael Serzan, MD (@mikeserzanmd) 's Twitter Profile Photo

💫 ADVANCEMENTS IN ONCOLOGY #AdvInOnc25 SignifyMD Delighted to join Oncology Brothers who are driving #MedEd and #SoMe forward through innovative podcasts and treatment algorithms for the practicing oncologist! 🤩A masterclass by Petros Grivas Enrique Grande highlighting

💫 ADVANCEMENTS IN ONCOLOGY 
 #AdvInOnc25 <a href="/SignifyMD/">SignifyMD</a> 

Delighted to join <a href="/OncBrothers/">Oncology Brothers</a> who are  driving #MedEd and #SoMe forward through innovative podcasts and treatment algorithms for the practicing oncologist! 

🤩A masterclass by <a href="/PGrivasMDPhD/">Petros Grivas</a> <a href="/drenriquegrande/">Enrique Grande</a> highlighting
Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

The curves everybody’s been waiting for. 

First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p&lt;0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.
Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

Morning > Afternoon for IO? Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat). Given IO’s long half-life, maybe only the timing of the first dose matters. #ASCO2025

Morning &gt; Afternoon for IO?
Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat).
Given IO’s long half-life, maybe only the timing of the first dose matters.
#ASCO2025
Dr. Iván R. González (@dr_ivanoncologo) 's Twitter Profile Photo

✨🚀 Neoadjuvant Nivolumab + Chemo Boosts Long‑Term Survival in Resectable NSCLC! 🫁💪 🎯 Objective: Evaluate whether adding nivolumab to platinum-based chemotherapy before surgery improves overall survival (OS) in patients with resectable stage IB–IIIA non‑small cell lung

✨🚀 Neoadjuvant Nivolumab + Chemo Boosts Long‑Term Survival in Resectable NSCLC! 🫁💪

🎯 Objective:
 Evaluate whether adding nivolumab to platinum-based chemotherapy before surgery improves overall survival (OS) in patients with resectable stage IB–IIIA non‑small cell lung
Dr. Iván R. González (@dr_ivanoncologo) 's Twitter Profile Photo

✨🔬 First-Line Triple Combo Doubles Survival in BRAF V600E mCRC! 🌟🩺 🎯 Objective: Verify if adding encorafenib (BRAF inhibitor) and cetuximab (EGFR antibody) to standard mFOLFOX6 chemotherapy improves outcomes in previously untreated BRAF V600E–mutant metastatic colorectal

✨🔬 First-Line Triple Combo Doubles Survival in BRAF V600E mCRC! 🌟🩺

🎯 Objective:
 Verify if adding encorafenib (BRAF inhibitor) and cetuximab (EGFR antibody) to standard mFOLFOX6 chemotherapy improves outcomes in previously untreated BRAF V600E–mutant metastatic colorectal
Erman Akkus (@erman_akkus) 's Twitter Profile Photo

❓Adjuvant/perioperative chemotherapy for curative liver metastesectomy of CRC? ESMO - Eur. Oncology #ESMOGI25 ✅Probably DFS but no OS benefit ✅decision should be individualized ❓ctDNA? 👉esmogastro.org/article/S2949-… #cancer #oncology #MedX #CRC OncoAlert Dr Joseph McCollom DO

❓Adjuvant/perioperative chemotherapy for curative liver metastesectomy of CRC? 
<a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMOGI25 

✅Probably DFS but no OS benefit
✅decision should be individualized
❓ctDNA? 

👉esmogastro.org/article/S2949-…

#cancer #oncology #MedX #CRC <a href="/OncoAlert/">OncoAlert</a> <a href="/realbowtiedoc/">Dr Joseph McCollom DO</a>
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Exercizumab is real. Aerobic exercise cut colon cancer recurrence + death. It’s time to combine movement with medicine not one or the other. #oncology #Cancer NEJM OncoAlert ASCO #ASCO25 DOI: 10.1056/NEJMoa2502760

Exercizumab is real.
Aerobic exercise cut colon cancer recurrence + death.
It’s time to combine movement with medicine  not one or the other.
#oncology #Cancer <a href="/NEJM/">NEJM</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/ASCO/">ASCO</a> #ASCO25 
DOI: 10.1056/NEJMoa2502760
PERONEGRO CAGA POLENTA (@garchanetta) 's Twitter Profile Photo

🇦🇷 Argentina es el único país del mundo en ganar el máximo torneo de fútbol, básquet y tenis en lo que va del Siglo XXI. - 🏀 Campeón olímpico 2004 - 🎾 Campeón de Copa Davis 2016 - ⚽️ Campeón del Mundo 2022

🇦🇷 Argentina es el único país del mundo en ganar el máximo torneo de fútbol, básquet y tenis en lo que va del Siglo XXI.

- 🏀 Campeón olímpico 2004
- 🎾 Campeón de Copa Davis 2016
- ⚽️ Campeón del Mundo 2022